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Original article
Worldwide, hypertension, type 2 diabetes, and Alzheimer’s 
disease (AD) are common public health problems esti-
mated to cause millions of premature deaths. In recent dec-
ades, hypertension and diabetes, as vascular risk factors, 
increase the risk of cognitive impairment and dementia.1 
Hypertension alone affects 33% of Americans presently. In 
2015, diabetes was estimated to affect 9.4% of the US adult 
population. However, exclusively above 65  years, the per-
centage increases to 25%. Regarding AD, 10% of individuals 
above 65 years suffer from the disease. There is a close link 
among these 3 diseases based on their risk factors, causes, 
pathological bases,2–5 and genetic factors, including lipo-
protein lipase gene in these 3 diseases.6 More evidence sup-
ports the link type 2 diabetes and hypertension with AD, the 
most common form of dementia. These 3 traits are caused 
by multiple susceptibility genes, whose effects are modulated 
by gene-environment and gene–gene interactions. Twin and 
family studies show low-to-moderate heritability for AD,7,8 
hypertension,9 and diabetes.10
Mendelian hypertension has elucidated certain bio-
logical pathways contributing to hypertension over dietary 
salt intake or directly through increased peripheral vascu-
lar resistance. The Mendelian mutation/genes exercise large 
effects on blood pressure–related phenotypes. However, 
genome wide association study (GWAS) and meta-analysis 
for blood pressure have yielded many signals with small 
effects.11 Thus far, few loci have been validated. Both genetic 
strategies are necessary, and much remains to be explored. 
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BACKGROUND
Hypertension affects 33% of Americans while type 2 diabetes and 
Alzheimer’s disease (AD) affect 10% of Americans, respectively. 
Ryanodine receptor 3 gene (RYR3) codes for the RYR which functions 
to release stored endoplasmic reticulum calcium ions (Ca2+) to increase 
intracellular Ca2+ concentration. Increasing studies demonstrate that 
altered levels of intracellular Ca2+ affect cardiac contraction, insulin secre-
tion, and neurodegeneration. In this study, we investigated associations 
of the RYR3 genetic variants with hypertension, AD, and diabetes.
METHODS
Family data sets were used to explore association of RYR3 polymorphisms 
with risk and age at onset (AAO) of hypertension, diabetes, and AD.
RESULTS
Family-based association tests using generalized estimating equa-
tions (FBAT–GEE) showed several unique or shared disease-1 
associated variants in the RYR3 gene. Three single nuclear polymor-
phisms (SNPs; rs2033610, rs2596164, and rs2278317) are significantly 
associated with risk for hypertension, diabetes, and AD. Two SNPs 
(rs4780174 and rs7498093) are significantly associated with AAO of 
the 3 diseases.
CONCLUSIONS
RYR3 variants are associated with hypertension, diabetes, and AD. 
Replication of these results of this gene in these 3 complex traits may 
help to better understand the genetic basis of calcium-signaling gene, 
RYR3 in association with risk and AAO of these diseases.
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Polymorphisms Within RYR3 Gene
Genetic/genomic insights and analyses of Mendelian hyper-
tension syndromes and GWAS on essential hypertension 
have contributed to the depth of understanding of the genet-
ics origins of hypertension.12 The results from several large-
scale studies have clearly shown that blood pressure–related 
single nuclear polymorphisms (SNPs) are associated with 
a difference in blood pressure and cardiovascular disease 
outcome.13
Type 2 diabetes is characterized by insulin resistance, 
obesity, and high blood pressure, each influenced by both 
genetic and environmental factors.14 Advanced diabetes is 
characterized with abnormal pancreatic islet β-cell func-
tion in presence of insulin.15 Insulin secretion is triggered by 
glucose, which is transported into the β-cells and metabo-
lized. This increases the concentration of adenosine triphos-
phate (ATP), which in turn leads to closure of ATP-sensitive 
K+ channels and depolarization of cellular membrane. 
Depolarization activates voltage-gated Ca2+ channels, allow-
ing entry of extracellular Ca2+ into β cells which triggers an 
even greater release of ER Ca2+ which is mediated by ryan-
odine receptors (RYRs). This suggests calcium-signaling 
pathway is involved in pathophysiology of diabetes.
The third complex trait is AD. It is characterized clinic-
ally by progressive deterioration of cognitive functions,16 
and physiologically by β-amyloid peptides (Aβ) aggre-
gates and intracellular neurofibrillar tangles composed of 
hyperphosphorylated microtubule-associated tau protein. 
While aging is the major risk factor, a high number of 
cases are characterized by earlier onset and are inherited 
in an autosomal dominant manner.17,18 In neurons, higher 
Ca2+ concentration, released by RYRs, leads to the release 
of neurotransmitter at synaptic junctions and affects den-
dritic action potential.19 The results from research studies 
suggest adults with type 2 diabetes have a higher risk of 
late-onset AD. Numerous investigations have reported that 
risk for late-onset AD is increased in the presence of type 
2 diabetes2,3 and hypertension.4 An estimated 54 million 
US adults have prediabetes and most of these people will 
develop type 2 diabetes within the next 10 years. Diabetes 
and hypertension raise the risk of heart disease and stroke. 
The pathophysiological factors include, but are not lim-
ited to, damaged blood vessels in the brain, increased 
insulin levels, unbalanced chemical changes, and high 
blood glucose. These changes may cause inflammation, 
damage brain cells, and increases risk for AD (https:// 
www.alz.org/national/documents/latino_ brochure_ 
diabetes.pdf). A  recent study focus on evaluation of 
amyloid-protective factors showed that hypertension, dia-
betes, and metabolic conditions were also associated with 
AD-like neurodegeneration.5
The critical roles of calcium-signaling pathway in all 3 
phenotypes lead us to think shared genetic variants in the 
genes involved in calcium signaling may be associated with 
these complex traits. We are interested in gene RYR3 located 
at 15q13.3. The protein encoded by RYR3 (Gene ID: 6263) is 
a RYR, which functions to release calcium from the ER. As 
a large intracellular homotetrameric protein (>2 MDa) that 
comprises 4,780 amino acids,20,21 RYRs reside on the sarco-
plasmic reticulum membrane and release Ca+2 from intra-
cellular stores to regulate concentration.22
Increased genes and mutations were reported to be associ-
ated with these traits based on the results of GWAS, candi-
date genes, meta-analysis, and next-generation sequencing 
studies. In the cardiovascular system, Ca+2 is essential for 
cardiac muscle contraction and relaxation, and acts as a 
second messenger in signal transduction pathways. Complex 
mechanisms regulate intracellular free calcium levels in the 
heart and vasculature, and a failure of these systems to main-
tain normal Ca+2 homeostasis has been linked to hyperten-
sion and other cardiovascular disease outcomes.22
Studies of the RYR3 have reported association with AD. 
For example, a meta-analysis based on 4 GWAS identified 
RYR3 association with AD risk using generalized multifac-
tor dimensionality reduction.23 Another study observed a 
significant interaction between RYR3 and CACNA1C (genes 
coding for calcium channels that mediate the influx of cal-
cium ions into the cell upon membrane polarization) in all 3 
independent data sets of Alzheimer’s Disease Neuroimaging 
Initiative cohorts.24 Functional studies of RYR3 suggest that 
upregulated RYR levels are found in human AD brains,25 
and RYR3 isoforms are upregulated at early and late stages 
of AD in animal models.26
Limited study of shared SNPs has been reported in hyper-
tension, diabetes, and AD. Based on previous findings 
and reasoning above, we hypothesized SNPs in RYR3 are 
involved in development of hypertension, diabetes, and AD.
MATERIALS AND METHODS
Subjects
A family-based sample was available from the National 
Institute on Aging–Late Onset Alzheimer’s Disease (NIA-
LOAD) family study: 2,545 individuals (1,266 cases includ-
ing 1,070 with age at onset [AAO] values) were available for 
our current study. Family Study: GWAS for Susceptibility 
Loci—Study Accession: phs000168.v1.p1. This study is to 
identify and recruit families with 2 or more siblings with 
the late-onset form of Alzheimer’s disease and a cohort of 
unrelated, nondemented controls similar in age and eth-
nic background, and to make the samples, the clinical and 
genotyping data and preliminary analyses available to quali-
fied investigators world-wide. Genotyping by the Center for 
Inherited Disease Research (CIDR) was performed using 
the Illumina Infinium II assay protocol with hybridization 
to Illumina Human 610Quadv1_B Beadchips. The details 
about these subjects were described elsewhere.27 Overall, 
1,266 AD cases and 1,279 non-AD individuals (including 
1,070 with AAO values) were from 1386 pedigrees (includ-
ing 589 nuclear families) (Table 1).
Hypertension is defined as systolic blood pressure of 
140  mm Hg or greater, diastolic blood pressure of 90  mm 
Hg or greater, or taking antihypertensive medication 
(phs000168.v1.p1). There were a total of 1,036 patients with 
hypertension and 1,240 control subjects.
Diabetes is defined by a history of diabetes or high blood 
sugar, or treatment of diabetes or high blood sugar reported 
by the subject. There are 247 patients with diabetes and 2,028 
control subjects. There are 279 SNPs within the RYR3 gene 
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Statistical methods
Genotype quality control: Hardy–Weinberg equilib-
rium was tested for all SNPs using the controls by using 
HAPLOVIEW version 4.1 software.28 Minor allele frequency 
was determined for each SNP and pairwise linkage disequi-
librium statistics (D′ and r2) were assessed using HAPMAP 
Caucasian data.
Family-based study: family-based association analyses for 
3 traits were performed using PBAT version 36.1,29 which 
can handle nuclear families with missing parental geno-
types, extended pedigrees with missing genotypic informa-
tion, analysis of SNPs, haplotype analysis, quantitative traits, 
and time-to-onset phenotypes. For the affection status of 
hypertension, diabetes, and AD, family-based association 
tests using generalized estimating equations (FBAT–GEE) 
was used to perform family-based association analysis For 
testing time-to-onset trait (AAO), FBAT–Wilcoxon statis-
tics were employed.30 The AAO values for healthy siblings 
were censored and age at entry into the study was used. 
Haplotype analysis was conducted in 2-SNP or 3-SNP slid-
ing windows. For multiple comparison, Bonferroni correc-
tion (α  =  0.05/279  =  1.79  ×  10−4) was used for statistical 
significance. Descriptive statistics were conducted with SAS 
9.4 (SAS Institute, Cary, NC). Three genetic models were 
used (allele-dose, dominant, and recessive).
In silico analysis
We evaluated potential function of the disease-associated 
SNP. We examined if these variants were located within the 
regions of the gene that might have potential functional 
importance. The sequences containing the associated SNPs 
were examined for microRNA-binding sites, splicing sites, 
regulatory gene regions, and species-conserved regions using 
NIH-SNP Function Prediction (http://snpinfo.niehs.nih.gov/
cgi-bin/snpinfo/snpfunc.cgi). To determine disease-associ-
ated SNPs with RYR3 expression levels in different human 
tissues, we used publicly available data from the Genotype-
Tissue Expression (GTEx) project31 in which, there is RNA 
sequencing on brain tissue from healthy donors available, 
resulting in genotype and expression phenotype data for 
~100–120 normal individuals in multiple different brain 
regions. The information about subjects and RNA quality can 
be found in the GTEx website (www.gtexportal.org).
RESULTS
Genotype quality control and descriptive statistics
Out of 279 SNPs in RYR3, 3 SNPs with P <10−4 for Hardy–
Weinberg equilibrium (HWE) were removed for further 
analysis. The demographic characteristics of the subjects in 
the study are shown in the Table 1. The mean AAO for AD, 
hypertension, and diabetes were 76.4, 60.3, and 61.9 years.
Single-marker and haplotype analyses based of risk of 
hypertension, diabetes, and AD using FBAT–GEE
We found shared disease-associated SNPs among these 
complex traits. A  number of SNPs were associated with 
each individual disease (Table  2), 5 SNPs (rs16973062, 
rs2288609, rs965471, rs4780167, rs10519874, and 
rs7498093) were associated with diabetes and also sur-
vived after the correction for multiple testing using the 
Bonferroni correction. Single-marker analysis showed 
that 3 SNPs (rs2033610, rs2596164, and rs2278317, 
P < 0.05) were associated with hypertension, diabetes, and 
AD in various genetic models (additive, dominant, and/or, 
recessive) as well as 3 SNPs (rs1390158, rs11637619, and 
rs8037864) also showed associations with hypertension 
and AD and 2 SNPs (rs4780167 and rs8028974) showed 
associations with hypertension and diabetes (P  <  0.05) 
without correction for multiple testing. Four disease-
associated SNPs (rs965471, rs10519874, rs7498093, and 
rs17236525) were shared between diabetes and AD in 
various genetic models. These results suggest shared gen-
etic susceptibility among these 3 diseases in the RYR3 
gene (Table 2).
We also identified haplotypes in association with 2 of 
3 traits, hypertension, and diabetes. The A-T haplotype 
from rs4780118 and rs11072471 (D′ = 0.87) and the A-C 
haplotype from rs2291736-rs937303 (D′  =  0.63) was sig-
nificantly associated with hypertension in the family-data 
(P = 0.00254 and 0.00667, respectively) (Table 3). Moreover, 
we also observed the G-G haplotype from rs12906709–
rs4780167 SNPs (P  =  2.71  ×  10−5), A-T haplotype of 
rs2288609–rs4780174 SNPs (P = 5.44 × 10−6), and the A-G 
haplotype from rs10519875–rs11855625 (P = 6.71 × 10−5) 
were significantly associated with diabetes in the family-
data (Table 3).
Table 1. Descriptive characteristics of cases and controls
Variable AD patients Controls Hypertension Controls Diabetes Controls
Sample size (n) 1,266 1,279 1,036 1,240 247 2,028
Sex
 Male 435 466 382 462 120 727
 Female 831 813 654 778 127 1,301
Mean AAO (years ± SD) 76.4 ± 6.7 – 60.3 ± 13.1 – 61.9 ± 12.2 –
Median AAO (years) 77 – 60 – 60 –
Range of age at onset (years) 50–98 – 22–91 – 35–89 –
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Single-marker analysis of age at onset of hypertension, 
diabetes, and AD in NIA-LOAD Family Study
In addition to exam RYR3 SNPs in association with 
the risks of 3 traits, we also tested these SNPs in asso-
ciation with AAO. The most significant association was 
revealed for rs10519818 which was shared by patients 
with hypertension (P = 0.000227 at both dominant and 
recessive models) and patients with diabetes (P = 0.0119 
at additive genetic model, Table  4). Another disease-
associated SNPs shared by hypertension and diabetes was 
rs12909478. Moreover, we also observed disease-associ-
ated SNPs shared by 3 diseases, they were rs7498093 and 
rs4780174 at the various genetic models (Table 4). Three 
disease-associated SNPs (rs17236525, rs12440440, and 
rs4238567) were also shared by diabetes and AD at the 
different genetic models (Table  4). These results, once 
again support the disease-risk SNPs and haplotypes in 
associations with AAO of hypertension and diabetes. 
The P values of all disease-associated SNPs in Table  4 
were before correction for multiple testing. A  com-
mon haplotype of A–C from rs2291736-rs937303 was 
associated with hypertension observed in 190 families 
(P  =  0.00667, Table  5) and the common haplotype of 
G–G of rs2288609–rs4780174 SNPs showed an associ-
ation with diabetes (P = 5.68 × 10−3).
Shared disease-associated SNPs and haplotype between 
the risk and AAO
We observed different disease-associated SNPs with 
disease risk and AAO; however, in the current study, we 
found several SNPs were associated not only with the disease 
risk, but also with AAO. SNP rs12440440 was found to be 
associated with diabetes risk (Table  2) and AAO for both 
diabetes and AD (Table 4). While SNP, rs17236525 was asso-
ciated with both risk and AAO for diabetes and AD (Table 2 
and 4). SNP rs2288609 was found to increase suscepti-
bility for AAO and risk of diabetes. Finally, rs7498093 was 
observed association with risk of diabetes and AD as well as 
AAO for 3 diseases at various genetic models (Table 2 and 4).
In silico analysis
To test if the associated SNPs were located at regulatory 
gene regions and species-conserved regions, we used NIH-
SNP Function Prediction. We found hypertension-associated 
SNPs, rs11072471 and rs16973323, were located at the species-
conserved region and the gene regulatory region, respectively, 
which suggests the regions containing biological function.32 
Having established strong associations of disease-associated 
SNPs with AAO and risk of AD, we tested if the genotype at 
these SNPs are associated with levels of gene expression in 
various tissues, including brain and adrenal gland based on 
the data from the Genotype-Tissue Expression. We hypothe-
sized the effects of the SNP genotypes on these 3 disease-risks 
may reflect genotype-based differences in levels of the gene 
expression. To investigate this, we analyzed recently released 
GTEx Consortium data. In postmortem samples from 100 to 
120 normal individuals from the GTEx data set, among the 
SNPs we tested, the homozygous genotypes (T/T) for minor 
alleles of all 3 diseases (AD, hypertension and diabetes) asso-
ciated SNP, rs2033610 were shown significantly decreased 
gene expression as compared with C/C and C/T genotypes in 
the adrenal glands (P = 2.6 × 10−7, Figure 1a). For rs2596164, 
GG genotype carriers showed the lowest levels of expression 
(P = 2.8 × 10−7) as compared with AG and AA genotypes in the 
adrenal glands (G is minor allele, Figure 1b). Finally, hyper-
tension- and AD-associated SNP, rs8037864, was also shown 
statistically significantly decreased gene expression of homo-
zygous GG genotype as compared with T/G and T/T geno-
types in the cells of transformed fibroblasts (P = 4.7 × 10−5).
DISCUSSION
Supporting our hypothesis, we identified unique and 
shared SNPs of RYR3 with hypertension, diabetes, and 
AD. In addition, the results of haplotype analyses and 
Table 3. Haplotypes associated with risk of hypertension and diabetes based on FBAT–GEE
SNPs r2a Haplotypeb Frequencyc Fam#d P-FBAT–GEEe
Hypertension
 rs4780118–rs11072471 0.87 A–T 0.59 222 0.00254
 rs2291736–rs937303 0.63 A–C 0.20 190 0.00667
Diabetes
 rs12906709–rs4780167 0.44 G–G 0.33 282 2.71 × 10−5
 rs2288609–rs4780174 0.41 A–T 0.27 216 5.44 × 10−6
 rs10519875–rs11855625 0.34 A–G 0.32 266 6.71 × 10−5
Abbreviations: FBAT–GEE, Family-based association tests using generalized estimating equations; SNP, single nuclear polymorphism.
aLinkage disequilibrium measure (r2).
bHaplotype inferred from 2 SNPs.
cHaplotype frequency.
dFam# refers to the number of informative families.
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disease-risk SNP function predictions of RYR3 support 
the role of its variants in these complex and multifactorial 
diseases. Furthermore, hypertension risk SNPs rs11072471 
and rs16973323 were found located at the species-well-con-
served region indicating functional importance of RYR3, 
which supports how important it is to identify potentially 
important conserved noncoding sequences in association 
with these complex diseases. A recent study reports an iden-
tification of a major quantitative trait locus on chromosome 
15q26 for systolic blood pressure (A logarithm of the odds 
[LOD] = 3.36), which is close to RYR gene location (15q13.3) 
in Mexican-Americans.33 Furthermore, 2 disease-associated 
SNPs (rs2033610 and rs2596164) also showed alterations 
of gene expression in the adrenal gland tissue, which plays 
an important role in secreting hormones that regulate both 
blood sugar and pressure. Additionally, a recent study has 
confirmed their previous findings of gene–gene interactions 
of RYR3 and CACNA1C in late-onset of AD using endo-phe-
notype analysis.34
Overall, results strongly imply the existence of shared 
SNPs associated of the RYR3 gene across these 3 diseases. 
A number of previous studies identified common genes and 
variants among diabetes, hypertension, and other pheno-
types,35 e.g., lipoprotein lipase gene is associated with hyper-
tension, AD, type 2 diabetes, and coronary heart disease.6 
There might be a pathophysiology mechanism of sharing 
genetic variants for these 3 traits, as previous studies sug-
gest that high glucose level and high blood pressure affect 
AD through multiple mechanisms, including reduction in 
cerebral blood flow36 and breakdown of the blood–brain 
barrier.37 A  recent study (39) has also showed that excess 
sugar in the blood can lead to organ and even brain dam-
age, which can lead to dementia as well as early onset of AD. 
It has been demonstrated that alterations of calcium (Ca2+)-
signaling pathway are involved in hypertension, diabetes, 
and AD based on functional studies.24,25 To the best of our 
knowledge, this is the first study of investigating the associ-
ation of RYR3 gene with the risk and AAO of hypertension, 
diabetes, and AD.
The strengths of this study include the comparatively 
medium sample size used which is of relatively large size 
for this type of study. The sample was also ethnically 
homogenous (US European decent), which gives indi-
cation that within this ethnic community the same gen-
etic evidence may be replicated. Multiple analyses were 
performed using single-marker analysis FBAT–GEE and 
FBAT–Wilcoxon. The RYRs associated variants were also 
supported by the results of haplotype and in-silico anal-
yses. We used a family-based design, which can reduce 
the type 1 error rate arising from population stratifica-
tion. Especially, the FBAT–GEE approach in the PBAT 
software can easily be adapted to scenarios with mul-
tiple offspring per family and missing parental informa-
tion, and testing for linkage disequilibrium under the 
assumption of linkage.38 We are also aware of some limi-
tations: among disease-associated SNPs, only 5 diabetes-
risk SNPs were retained after multiple testing using the 
Bonferroni correction, other unique and shared SNPs did 
not; however, it is well known that Bonferroni correc-
tion is a very conservative method. Moreover, we cannot 
exclude contribution from environmental or behavioral 
factors or other nongenetic correlations. Additional rep-
lication of these results is also necessary. Finally, our cur-
rent findings might be spurious or subject to type I error. 
Future confirmatory studies of the RYR3 in these 3 traits 
in independent samples or targeted genome sequencing 
of the gene for these diseases may provide an opportun-
ity to dissect the genetic complexity of this gene more 
accurately.
In conclusion, we provide genetic evidence of unique 
and shared disease-associated RYR3 polymorphisms 
among hypertension, diabetes, and AD. Suggesting an 
etiologic relationship between them, calcium disturbances 
and certain calcium-signaling pathways may be involved 
in pathophysiology of these traits. These results will pro-
vide a basis for replication in larger samples and/or other 
populations to elucidate the potential role of these genetic 
variants.
Table 5. Haplotypes associated with age at onset of hypertension and diabetes based on FBAT–Wilcoxon test
SNPs r2a Haplotypeb Frequencyc Fam#d P-FBAT–GEEe
Hypertension
 rs2596240–rs8023659 0.30 A–G 0.03 22 0.00888
 rs2291736–rs937303 0.63 A–C 0.20 190 0.00667
Diabetes
 rs16970801–rs16970823 0.70 C–A 0.06 20 0.00949
 rs2288609–rs4780174 0.41 G–G 0.43 44 0.00568
Abbreviations: FBAT–GEE, Family-based association tests using generalized estimating equations; SNP, single nuclear polymorphism.
aLinkage disequilibrium measure (r2).
bHaplotype inferred from 2 SNPs.
cHaplotype frequency.
dFam# refers to the number of informative families.
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